lapatinib,capecitabine,ado-trastuzumab emtansine,trastuzumab,trastuzumab deruxtecan
daiichi sankyo,astrazeneca,roche
['destiny,breast,2', 'breast', 'destiny,breast,3', 't-dxd', 'destiny,breast,6']
komen scholar alumni ian krop presented destiny-breast studies at #asco23, showing t-dxd was effective and beneficial to her2+ #breastcancer patients over age 65, even w/ slightly worse side effects. 
A force united by a promise to end breast cancer, funding groundbreaking research, community health & advocacy programs globally.
https://t.co/dvoS7vv1mZ